Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class

Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class

Potential Acquirer	Potential Use of LPBI IP by Asset Class	Assumptions IP Class #1 Journal	Assumptions IP Class #2 Books	Assumptions IP Class #3 e-Proceedings
Holding Company and Investment Bankers	Invest in product marketing of three Lines of Business
Information Technology Companies – Health Care	Use contents in application development
Scientific Publishers	Horizontal merger New Contents
Big Pharma	Vertical Integration with a production factor 1. Drug Discovery Process 2. Clinical Trial 3. Drug Repurposing
Internet Health Care Media	Horizontal merger
Education	Content is King
Health Insurance Companies & HMOs	Optimization of Treatment: Efficacy vs cost of treatment
Medical and Pharma Associations	Content is King
Information Syndicators Reuters’ Clarivate	Text Mining
Global Biotech & Pharmaceutical Conference Organizers	Information for Attendees
CRO & CRA	Text Mining for Indication and off label in Clinical Trial Design and After Market Efficacy Monitoring

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,459 other subscribers
Recent Posts
- Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
- The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
- Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
- Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
- Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
- Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
- Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
- Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
- 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
- Verily announced other organizational changes, 1/13/2023 January 16, 2023
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: